The translational journey of cancer nanomedicines: biological and entrepreneurial lessons learned
- PMID: 40304889
- DOI: 10.1007/s13346-025-01867-z
The translational journey of cancer nanomedicines: biological and entrepreneurial lessons learned
Abstract
Despite exhaustive investments, the breakthrough potential of nanomedicines (NM) is not yet realized. Whilst Doxil and covid-19 vaccines demonstrated certain benefits, many NM failed in clinical development. Lies the true reason for this limited success in inappropriate assumptions, incorrect approaches, or other omissions? This note describes the translational journey of CPC634 (docetaxel entrapping core-crosslinked polymeric micelles) and illustrates lessons learned in drug product development. Scientific elements are to understand the pathophysiology of the diseased tissue, the journey of NM upon administration and resulting drug release and the induced pharmacodynamic effects over time, particularly in actual patients. Industrial elements comprise market-product fit, target product profile, competitive benchmarking, while development efficiency focuses to generate a positive business case. A goal-oriented product design which is validated by external experts increases chances of development success and assures investor-readiness. NM development will progress by aligning fundamental biological insights with industrial product requirements, driving therapeutic breakthroughs.
Keywords: Cancer nanomedicines; Clinical evaluation; Entrepreneurial aspects spinoff; Fundamental biological insights; Translational development.
© 2025. Controlled Release Society.
Conflict of interest statement
Declarations. Ethics approval and consent to participate: Not relevant. Consent for publication: CR. Competing interests: CR is shareholder of Cristal Therapeutics and Liberates.
Similar articles
-
Survey of Clinical Translation of Cancer Nanomedicines-Lessons Learned from Successes and Failures.Acc Chem Res. 2019 Sep 17;52(9):2445-2461. doi: 10.1021/acs.accounts.9b00228. Epub 2019 Aug 19. Acc Chem Res. 2019. PMID: 31424909 Review.
-
Design, development and clinical translation of CriPec®-based core-crosslinked polymeric micelles.Adv Drug Deliv Rev. 2022 Dec;191:114613. doi: 10.1016/j.addr.2022.114613. Epub 2022 Nov 4. Adv Drug Deliv Rev. 2022. PMID: 36343757 Review.
-
New ways of insulin delivery.Int J Clin Pract Suppl. 2011 Feb;(170):31-46. doi: 10.1111/j.1742-1241.2010.02577.x. Int J Clin Pract Suppl. 2011. PMID: 21323811 Review.
-
Physiological determinants and plausible '6R' roadmap for clinical success of nanomedicines.Nanomedicine (Lond). 2023 Aug;18(18):1207-1222. doi: 10.2217/nnm-2023-0114. Epub 2023 Aug 31. Nanomedicine (Lond). 2023. PMID: 37650539 Review.
-
Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status.Adv Drug Deliv Rev. 2013 Oct;65(10):1284-98. doi: 10.1016/j.addr.2013.08.012. Epub 2013 Sep 6. Adv Drug Deliv Rev. 2013. PMID: 24018362 Review.
References
-
- Vargason AM, Anselmo AC, Mitragotri S. The evolution of commercial drug delivery technologies. Nat Biomed Eng. 2021;5(9):951–67. https://doi.org/10.1038/s41551-021-00698-w . - DOI - PubMed
-
- Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol. 1965;13(1):238–52. https://doi.org/10.1016/s0022-2836(65)80093-6 . - DOI - PubMed
-
- https://pmc.ncbi.nlm.nih.gov/ . Accessed January 16, 2025
-
- Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33(9):941–51. https://doi.org/10.1038/nbt.3330 . - DOI - PubMed - PMC
LinkOut - more resources
Full Text Sources